Comparison of risankizumab and upadacitinib treatment persistence according to disease location in patients with Crohn’s disease: data from the CREdIT registry

Clicks: 12
ID: 337534
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #95 of 101 articles by views in inflammatory bowel diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Importance Comparative data on risankizumab and upadacitinib in Crohn’s disease are limited. Objective We aimed to compare the real-world effectiveness of the 2 therapies, measured by treatment persistence, and to assess whether it differed according to disease location. Design Retrospective cohort study. Setting Nationwide CREdIT prospective registry. Participants Pediatric and adult patients with Crohn’s disease. Exposures Initiation of risankizumab or upadacitinib. Main Outcomes and Measures The primary outcome was treatment persistence, defined as time from therapy initiation to drug discontinuation, with censoring at the last follow-up, and evaluated using weighted Cox models clustered by patient. Missing covariates were handled using multiple imputation, and treatment groups were balanced using inverse probability weighting (IPW) based on propensity scores. Results A total of 560 treatment observations were included (264 risankizumab and 296 upadacitinib), most representing advanced lines of therapy. Following IPW, upadacitinib was associated with a higher risk of treatment discontinuation than risankizumab (Hazard ratio [HR] 1.86, 95% CI, 1.02-3.39). Among patients with ileal involvement (L1/L3), upadacitinib was associated with a higher discontinuation risk (HR 2.56, 95% CI, 1.49-4.40), whereas no difference was observed in patients with isolated colonic disease (L2; HR 0.66, 95% CI, 0.19-2.33). The interaction between upadacitinib therapy and isolated colonic involvement was significant (P = .049). Conclusions and Relevance In this nationwide real-world cohort of predominantly advanced treatment-experienced patients with Crohn’s disease, risankizumab was associated with greater treatment persistence than upadacitinib. The superiority of risankizumab was observed mainly in patients with ileal involvement, and these findings suggest that disease location may be an important consideration when choosing between the 2 therapies.
Reference Key
openalex_W7224096764 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ondřej Hradský, Dana Ďuricová, Milan Lukáš, Lenka Nedbalová, Luděk Bouchner, Barbora Pipek, Pavel Svoboda, Tomáš Douda, Petra Mináriková, Milan Široký, Přemysl Falt, Jana Koželuhová, Tomáš Vaňásek, Ivana Mikoviny Kajzrlikova, Jiri Stehlik, Jan Schwarz, Jiří Bronský, Martin Bortlík
Journal inflammatory bowel diseases
Year 2026
DOI
10.1093/ibd/izag224
URL
https://doi.org/10.1093/ibd/izag224
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.